Scroll

dipyridamole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	924	58-32-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: dipyridamole cardoxil cardoxin cleridium dipyridamine dipyridamol dipyridan peridamol persantin stenocardil stimolcardio	A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) Molecular weight: 504.64 Formula: C24H40N8O4 CLOGP: 2.21 LIPINSKI: 2 HAC: 12 HDO: 4 TPSA: 145.44 ALOGS: -2.74 ROTB: 12 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

dipyridamole
cardoxil
cardoxin
cleridium
dipyridamine
dipyridamol
dipyridan
peridamol
persantin
stenocardil
stimolcardio

A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)

Molecular weight: 504.64
Formula: C24H40N8O4
CLOGP: 2.21
LIPINSKI: 2
HAC: 12
HDO: 4
TPSA: 145.44
ALOGS: -2.74
ROTB: 12

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.40	g	O
0.20	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.01 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.10 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	13.21 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	50 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.82 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.01 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	13 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 6, 1961	FDA	BOEHRINGER INGELHEIM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sedation complication	1369.99	24.84	327	8256	13495	63466944
Creatinine renal clearance decreased	1321.27	24.84	328	8255	15980	63464459
Blood calcium decreased	1177.64	24.84	331	8252	26120	63454319
Orthostatic hypotension	1109.55	24.84	339	8244	35821	63444618
Sedation	1064.92	24.84	334	8249	38475	63441964
Cognitive disorder	995.80	24.84	347	8236	55468	63424971
Depressed level of consciousness	937.19	24.84	341	8242	61737	63418702
Balance disorder	831.82	24.84	340	8243	84082	63396357
Mobility decreased	683.21	24.84	330	8253	120829	63359610
Constipation	531.67	24.84	346	8237	224597	63255842
Hypotension	478.22	24.84	349	8234	272255	63208184
Fall	441.79	24.84	387	8196	391947	63088492
Toxicity to various agents	376.07	24.84	291	8292	246959	63233480
Pain	184.24	24.84	344	8239	740284	62740155
Drug ineffective	89.16	24.84	17	8566	1044748	62435691
Multiple drug therapy	77.64	24.84	26	8557	3620	63476819
Fatigue	47.55	24.84	31	8552	887997	62592442
Abdominal discomfort	32.46	24.84	3	8580	320882	63159557
Arthralgia	30.24	24.84	20	8563	569690	62910749
Joint swelling	28.48	24.84	5	8578	327661	63152778
Neurological symptom	27.19	24.84	14	8569	5769	63474670
Drug intolerance	26.20	24.84	5	8578	308656	63171783
Weight increased	24.93	24.84	3	8580	260789	63219650

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Labelled drug-drug interaction medication error	37.52	18.74	23	4176	14916	34937816
Cerebral haemorrhage	37.30	18.74	32	4167	34905	34917827
Peritoneal haematoma	33.52	18.74	6	4193	63	34952669
Splenic injury	30.41	18.74	5	4194	30	34952702
Cerebrovascular accident	27.80	18.74	42	4157	84769	34867963
Hypotension	27.51	18.74	73	4126	221576	34731156
Vitreous haemorrhage	25.87	18.74	10	4189	2363	34950369
Tubulointerstitial nephritis	23.95	18.74	20	4179	21004	34931728
Embolic stroke	22.81	18.74	11	4188	4443	34948289
Intra-abdominal haemorrhage	22.25	18.74	9	4190	2395	34950337
Haemorrhage intracranial	22.06	18.74	17	4182	15929	34936803
Monocytosis	21.92	18.74	6	4193	475	34952257
Abdominal sepsis	21.35	18.74	7	4192	1028	34951704
Gastrointestinal haemorrhage	21.13	18.74	38	4161	88439	34864293
Ocular myasthenia	20.89	18.74	5	4194	231	34952501
Livedo reticularis	19.38	18.74	8	4191	2241	34950491
Drug interaction	19.08	18.74	65	4134	225881	34726851
Bronchitis chronic	19.01	18.74	7	4192	1449	34951283
Intraventricular haemorrhage	18.93	18.74	9	4190	3522	34949210

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sedation complication	1331.87	19.45	338	12221	15331	79716498
Creatinine renal clearance decreased	1257.69	19.45	336	12223	18666	79713163
Blood calcium decreased	1111.89	19.45	342	12217	31477	79700352
Orthostatic hypotension	950.84	19.45	350	12209	55814	79676015
Sedation	947.67	19.45	342	12217	51553	79680276
Cognitive disorder	939.46	19.45	368	12191	69558	79662271
Depressed level of consciousness	798.82	19.45	360	12199	96292	79635537
Balance disorder	775.23	19.45	355	12204	98502	79633327
Mobility decreased	656.92	19.45	339	12220	121836	79609993
Constipation	449.06	19.45	364	12195	282686	79449143
Hypotension	421.82	19.45	426	12133	439891	79291938
Fall	356.33	19.45	409	12150	487220	79244609
Toxicity to various agents	233.39	19.45	308	12251	421232	79310597
Pain	188.33	19.45	369	12190	703433	79028396
Multiple drug therapy	70.89	19.45	26	12533	4052	79727777
Drug ineffective	57.13	19.45	52	12507	1080861	78650968
Fatigue	52.41	19.45	42	12517	929685	78802144
Arthralgia	33.19	19.45	25	12534	571778	79160051
Cerebral haemorrhage	29.92	19.45	41	12518	57632	79674197
Joint swelling	29.49	19.45	5	12554	288641	79443188
Product dose omission issue	28.34	19.45	3	12556	247534	79484295
Peritoneal haematoma	25.21	19.45	6	12553	205	79731624
Abdominal discomfort	24.20	19.45	5	12554	250722	79481107
Weight increased	23.92	19.45	7	12552	277379	79454450
Embolic stroke	23.73	19.45	15	12544	7811	79724018
Cerebrovascular accident	23.06	19.45	65	12494	155227	79576602
Vitreous haemorrhage	21.87	19.45	11	12548	3702	79728127
Completed suicide	21.56	19.45	6	12553	245761	79486068
Cerebral infarction	21.50	19.45	31	12528	45645	79686184
Infusion related reaction	21.39	19.45	5	12554	230232	79501597
Neurological symptom	19.79	19.45	14	12545	8769	79723060
Death	19.76	19.45	37	12522	566477	79165352
Off label use	19.73	19.45	75	12484	907140	78824689
Labelled drug-drug interaction medication error	19.65	19.45	23	12536	27627	79704202

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	B01AC07	BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Platelet aggregation inhibitors excl. heparin
FDA PE	N0000008832	Decreased Platelet Aggregation
FDA EPC	N0000175578	Platelet Aggregation Inhibitor
CHEBI has role	CHEBI:35620	vasodilator agents
CHEBI has role	CHEBI:50427	platelet aggregation inhibitors
CHEBI has role	CHEBI:50445	adenosine deaminase inhibitors
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D006401	Hematologic Agents
MeSH PA	D010726	Phosphodiesterase Inhibitors
MeSH PA	D010975	Platelet Aggregation Inhibitors
MeSH PA	D014665	Vasodilator Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Chronic heart failure	indication	48447003
Atrial fibrillation	indication	49436004	DOID:0060224
Platelet Aggregation Inhibition	indication
Prevention of Cerebral Thrombosis	indication
Myocardial Perfusion Imaging Adjunct	indication
Cerebral embolism	off-label use	75543006	DOID:4372
Transient ischemic attack	off-label use	266257000	DOID:224
Thromboembolic disorder	off-label use	371039008
Myocardial Reinfarction Prevention	off-label use
Alcoholism	contraindication	7200002
Poisoning by digitalis glycoside	contraindication	12876009
Peptic ulcer	contraindication	13200003	DOID:750
Senile cardiac amyloidosis	contraindication	16573007
Myocardial infarction	contraindication	22298006	DOID:5844
Sick sinus syndrome	contraindication	36083008	DOID:13884
Gastrointestinal ulcer	contraindication	40845000
Myxedema	contraindication	43153006	DOID:11634
Hypokalemia	contraindication	43339004
Low blood pressure	contraindication	45007003
Sinus bradycardia	contraindication	49710005
Myocarditis	contraindication	50920009	DOID:820
Vitamin K deficiency	contraindication	52675005	DOID:11249
Nasal polyp	contraindication	52756005
Acute nephropathy	contraindication	58574008
Hypercalcemia	contraindication	66931009	DOID:12678
Ventricular fibrillation	contraindication	71908006
Factor II deficiency	contraindication	73975000
Reye's syndrome	contraindication	74351001	DOID:14525
Wolff-Parkinson-White pattern	contraindication	74390002	DOID:384
Gastrointestinal hemorrhage	contraindication	74474003
Thrombotic thrombocytopenic purpura	contraindication	78129009	DOID:10772
Cor pulmonale	contraindication	83291003	DOID:8515
Constrictive pericarditis	contraindication	85598007	DOID:11481
Gout	contraindication	90560007	DOID:13189
Kidney disease	contraindication	90708001	DOID:557
Hemophilia	contraindication	90935002
Anemia due to enzyme deficiency	contraindication	111577008
von Willebrand disorder	contraindication	128105004	DOID:12531
Hypomagnesemia	contraindication	190855004
Atrioventricular block	contraindication	233917008	DOID:0050820
Disease of liver	contraindication	235856003	DOID:409
Anemia	contraindication	271737000	DOID:2355
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Idiopathic hypertrophic subaortic stenosis	contraindication	360465008
Acute coronary syndrome	contraindication	394659003
Breastfeeding (mother)	contraindication	413712001
Restrictive cardiomyopathy	contraindication	415295002	DOID:397
Acute erosive gastritis	contraindication	444926003

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.0	Basic
pKa2	8.52	Basic
pKa3	2.75	Basic
pKa4	2.12	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Enzyme	Q9Y233	PDE10_HUMAN	INHIBITOR	Ki	6	CHEMBL	CHEMBL
cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Enzyme	P27815	PDE4A_HUMAN	INHIBITOR	IC50	5.80	DRUG MATRIX	CHEMBL
Phosphodiesterase 3	Enzyme	Q13370 Q14432	PDE3B_HUMAN PDE3A_HUMAN	INHIBITOR	IC50	4.37	CHEMBL	CHEMBL
Phosphodiesterase 7	Enzyme	Q13946 Q9NP56	PDE7A_HUMAN PDE7B_HUMAN	INHIBITOR	Ki	6.22	CHEMBL	CHEMBL
Phosphodiesterase 6	Enzyme	O43924 P16499 P18545 P35913 P51160 Q13956	PDE6D_HUMAN PDE6A_HUMAN CNRG_HUMAN PDE6B_HUMAN PDE6C_HUMAN CNCG_HUMAN	INHIBITOR	Ki	6.90	CHEMBL	CHEMBL
Phosphodiesterase 1	Enzyme	P54750 Q01064 Q14123	PDE1A_HUMAN PDE1B_HUMAN PDE1C_HUMAN	INHIBITOR	IC50	4.35	CHEMBL	CHEMBL
Equilibrative nucleoside transporter 1	Transporter	Q99808	S29A1_HUMAN	INHIBITOR	Ki	8.50	CHEMBL	CHEMBL
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8B	Enzyme	O95263	PDE8B_HUMAN	INHIBITOR	IC50	4.30	IUPHAR	CHEMBL
cGMP-dependent 3',5'-cyclic phosphodiesterase	Enzyme	O00408	PDE2A_HUMAN	INHIBITOR	IC50	5.49	CHEMBL	CHEMBL
cAMP-specific 3',5'-cyclic phosphodiesterase 7B	Enzyme	Q9NP56	PDE7B_HUMAN	INHIBITOR	IC50	6	CHEMBL	CHEMBL
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A	Enzyme	O60658	PDE8A_HUMAN	INHIBITOR	IC50	5.10	CHEMBL	CHEMBL
cGMP-specific 3',5'-cyclic phosphodiesterase	Enzyme	O76074	PDE5A_HUMAN	INHIBITOR	IC50	6.28	CHEMBL	CHEMBL
ATP-binding cassette sub-family G member 2	Transporter	Q9UNQ0	ABCG2_HUMAN		IC50	5.19	CHEMBL
Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A	Enzyme	Q9HCR9	PDE11_HUMAN		Ki	6.40	CHEMBL
Equilibrative nucleoside transporter 4	Transporter	Q7RTT9	S29A4_HUMAN	INHIBITOR	Ki	5.90	IUPHAR
Protein prune homolog	Enzyme	Q86TP1	PRUNE_HUMAN		IC50	6.11	CHEMBL
Sodium/nucleoside cotransporter 1	Transporter	O00337	S28A1_HUMAN	INHIBITOR	Ki	7.54	DRUG MATRIX
Replicase polyprotein 1ab	Enzyme		R1AB_SARS2	INHIBITOR	IC50	6.26	SCIENTIFIC LITERATURE
Arachidonate 15-lipoxygenase	Enzyme		LOX15_RABIT		IC50	5.16	DRUG MATRIX
Cyclic nucleotide phosphodiesterase PDE3A	Enzyme		Q9XSW7_PIG		IC50	4.36	CHEMBL
Cyclic AMP-specific phosphodiesterase SSPDE4A1A	Enzyme		O77823_PIG		IC50	5.28	CHEMBL
ORF 73	Unclassified		O40947_HHV8		AC50	5.05	CHEMBL

External reference:

ID	Source
4017884	VUID
N0000146237	NUI
D00302	KEGG_DRUG
203015	RXNORM
4017884	VANDF
C0012582	UMLSCUI
CHEBI:4653	CHEBI
H9F	PDB_CHEM_ID
CHEMBL932	ChEMBL_ID
D004176	MESH_DESCRIPTOR_UI
DB00975	DRUGBANK_ID
4807	IUPHAR_LIGAND_ID
1545	INN_ID
64ALC7F90C	UNII
3108	PUBCHEM_CID
2493	MMSL
2527	MMSL
3353	MMSL
4619	MMSL
d00213	MMSL
000691	NDDF
387371005	SNOMEDCT_US
66859009	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Dipyridamole	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1070	TABLET	25 mg	ORAL	ANDA	19 sections
Dipyridamole	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1070	TABLET	25 mg	ORAL	ANDA	19 sections
Dipyridamole	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1071	TABLET	50 mg	ORAL	ANDA	19 sections
Dipyridamole	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1071	TABLET	50 mg	ORAL	ANDA	19 sections
Dipyridamole	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1072	TABLET	75 mg	ORAL	ANDA	19 sections
Dipyridamole	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1072	TABLET	75 mg	ORAL	ANDA	19 sections
Dipyridamole	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9852	INJECTION	5 mg	INTRAVENOUS	ANDA	11 sections
Dipyridamole	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9852	INJECTION	5 mg	INTRAVENOUS	ANDA	11 sections
Dipyridamole	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1461	TABLET, FILM COATED	25 mg	ORAL	ANDA	21 sections
Dipyridamole	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1461	TABLET, FILM COATED	25 mg	ORAL	ANDA	21 sections
Dipyridamole	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1462	TABLET, FILM COATED	50 mg	ORAL	ANDA	21 sections
Dipyridamole	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1462	TABLET, FILM COATED	50 mg	ORAL	ANDA	21 sections
Dipyridamole	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1463	TABLET, FILM COATED	75 mg	ORAL	ANDA	21 sections
Dipyridamole	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1463	TABLET, FILM COATED	75 mg	ORAL	ANDA	21 sections
Dipyridamole	HUMAN PRESCRIPTION DRUG LABEL	1	0641-2569	INJECTION	5 mg	INTRAVENOUS	ANDA	19 sections
Dipyridamole	HUMAN PRESCRIPTION DRUG LABEL	1	0641-2569	INJECTION	5 mg	INTRAVENOUS	ANDA	19 sections
Aspirin and Extended - Release Dipyridamole Capsules, 25 mg / 200 mg	HUMAN PRESCRIPTION DRUG LABEL	2	0904-7056	CAPSULE	200 mg	ORAL	ANDA	25 sections
Aspirin and Dipyridamole	HUMAN PRESCRIPTION DRUG LABEL	2	16714-964	CAPSULE, EXTENDED RELEASE	200 mg	ORAL	ANDA	26 sections
Aggrenox	HUMAN PRESCRIPTION DRUG LABEL	2	21695-656	CAPSULE	200 mg	ORAL	NDA	17 sections
Aspirin and Extended-Release Dipyridamole	HUMAN PRESCRIPTION DRUG LABEL	2	42291-116	CAPSULE	200 mg	ORAL	ANDA	26 sections
ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE	HUMAN PRESCRIPTION DRUG LABEL	2	42571-274	CAPSULE, EXTENDED RELEASE	200 mg	ORAL	ANDA	26 sections
ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE	HUMAN PRESCRIPTION DRUG LABEL	2	42571-274	CAPSULE, EXTENDED RELEASE	200 mg	ORAL	ANDA	26 sections
Aspirin and Dipyridamole	HUMAN PRESCRIPTION DRUG LABEL	2	43598-339	CAPSULE, EXTENDED RELEASE	200 mg	ORAL	ANDA	26 sections
Aspirin and Dipyridamole Extended Release	Human Prescription Drug Label	2	47335-927	CAPSULE	200 mg	ORAL	ANDA	25 sections
Aspirin and Extended - Release Dipyridamole Capsules, 25 mg / 200 mg	HUMAN PRESCRIPTION DRUG LABEL	2	49884-007	CAPSULE	200 mg	ORAL	ANDA	25 sections
Aspirin and Extended - Release Dipyridamole Capsules, 25 mg / 200 mg	HUMAN PRESCRIPTION DRUG LABEL	2	49884-007	CAPSULE	200 mg	ORAL	ANDA	25 sections
Aspirin and Extended-Release Dipyridamole	HUMAN PRESCRIPTION DRUG LABEL	2	51407-271	CAPSULE, EXTENDED RELEASE	200 mg	ORAL	ANDA	19 sections
Dipyridamole	HUMAN PRESCRIPTION DRUG LABEL	1	51407-626	TABLET, FILM COATED	25 mg	ORAL	ANDA	17 sections
Dipyridamole	HUMAN PRESCRIPTION DRUG LABEL	1	51407-627	TABLET, FILM COATED	50 mg	ORAL	ANDA	17 sections
Dipyridamole	HUMAN PRESCRIPTION DRUG LABEL	1	51407-628	TABLET, FILM COATED	75 mg	ORAL	ANDA	17 sections